On June 14, 2022 HALO Diagnostics, a precision diagnostics leader, reported that it has joined forces with the Genomic Testing Cooperative (GTC) to offer innovative, personalized testing to its physician network and 1M+ patients served (Press release, Genomic Testing Cooperative, JUN 14, 2022, View Source [SID1234615999]). This solution combines HALO Diagnostics’ clinical ensemble and image-guided therapies with GTC’s genomic profiling of a patient’s DNA / RNA using liquid biopsy and tissue samples. Together, the companies will help patients on every step of their unique healthcare journey – from detection and diagnosis to prognosis and treatment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For decades, patients have faced a one-size-fits-all approach to their health. They are now calling for more prompt, personalized care. With this partnership, HALO Diagnostics and GTC are ready to answer this call.
Recent therapeutic approvals in HALO Diagnostics’ core clinical areas such as prostate, breast, and lung cancers have focused on targeted therapies and immunotherapies. Before treatment can begin, patients undergo biomarker testing. This is where GTC comes in: The company’s comprehensive test panels simultaneously query key DNA / RNA alterations, guiding decision making for patients’ treatment plans.
"By bringing together advanced imaging and molecular biomarkers, HALO Diagnostics and GTC will have a unique impact on driving early detection in healthcare," says Dr. John Feller, Chief Medical Officer at HALO Diagnostics. "We will reduce oversights common in individual diagnostic tests, making early detection, minimally invasive therapies, and precision-focused healthcare possible."
Dr. Maher Albitar, GTC’s Founder, CEO, and Chief Medical Officer, agrees. "Combining imaging with molecular profiling is not only a natural expansion in medical diagnostics, but also provides a unique opportunity for innovation in the era of artificial intelligence." He adds, "We are very excited to be working with HALO Diagnostics. This collaboration will save patient lives and accelerate the development of key radiogenomic biomarkers."
With this partnership, the innovation is just beginning.
GTC recently showcased Liquid Trace, its latest liquid biopsy test that combines cell-free DNA and cell-free RNA to improve the test’s sensitivity for diagnosing solid tumours and blood-related cancers, at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s annual meeting from June 3-7, 2022. The Liquid Trace test is now available to HALO Diagnostics’ patients indicated for this precision-focused approach.